Smoking cessation medication prescriptions in patients with T2DM and TUD (with obesity) (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
4,649	semaglutide	insulins	190 (4.1%)	488 (10.5%)	-6.4% (-7.5%, -5.4%) -		0.35 (0.30-0.42)
4,652	semaglutide	metformin	190 (4.1%)	330 (7.1%)	-3.0% (-3.9%, -2.1%)	⊢	0.56 (0.47–0.67)
3,514	semaglutide	DPP-4i	119 (3.4%)	258 (7.3%)	-4.0% (-5.0%, -2.9%)	├-	0.44 (0.36–0.55)
3,617	semaglutide	SGLT2i	137 (3.8%)	221 (6.1%)	-2.3% (-3.3%, -1.3%)	├-	0.60 (0.48–0.74)
4,056	semaglutide	SU	155 (3.8%)	281 (6.9%)	-3.1% (-4.1%, -2.1%)	⊢ ■─┤	0.53 (0.44–0.65)
1,609	semaglutide	TZD	55 (3.4%)	84 (5.2%)	-1.8% (-3.2%, -0.4%)	├	0.63 (0.45–0.89)
4,018	semaglutide	other GLP-1RAs	160 (4.0%)	233 (5.8%)	-1.8% (-2.8%, -0.9%)	├-	0.67 (0.55–0.82)
					0.3	0 0.40 0.60 0.801.0 Hazard Raf	